Product Description
Mechanisms of Action: Gln Analogue
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Enshi Tujia and Miao Autonomous Prefecture Central Hospital
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ChiCTR2000040968 | N/A |
Recruiting |
Ischemic Stroke |
2023-12-10 |
|
ChiCTR-IIR-16009298 | N/A |
Recruiting |
Lung Cancer|Breast Cancer|Ovarian Cancer |
2017-10-10 |
|
ChiCTR2000031123 | N/A |
Not yet recruiting |
Unknown |
None |